CN112771045A - 喹啉并吡咯烷-2-酮类衍生物及其应用 - Google Patents

喹啉并吡咯烷-2-酮类衍生物及其应用 Download PDF

Info

Publication number
CN112771045A
CN112771045A CN201980064561.9A CN201980064561A CN112771045A CN 112771045 A CN112771045 A CN 112771045A CN 201980064561 A CN201980064561 A CN 201980064561A CN 112771045 A CN112771045 A CN 112771045A
Authority
CN
China
Prior art keywords
compound
isomer
pharmaceutically acceptable
acceptable salt
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980064561.9A
Other languages
English (en)
Other versions
CN112771045B (zh
Inventor
钱文远
杨纯道
代国强
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN112771045A publication Critical patent/CN112771045A/zh
Application granted granted Critical
Publication of CN112771045B publication Critical patent/CN112771045B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

公开了一系列喹啉并吡咯烷‑2‑酮类的化合物，及其在制备ATM抑制剂相关疾病的药物中的应用。具体涉及了式(Ι)所示衍生化合物、其互变异构体或其药学上可接受的组合物。
Figure DDA0003000032560000011

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201980064561.9A 2018-09-30 2019-09-27 喹啉并吡咯烷-2-酮类衍生物及其应用 Active CN112771045B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811157825 2018-09-30
CN2018111578259 2018-09-30
PCT/CN2019/108520 WO2020063855A1 (zh) 2018-09-30 2019-09-27 喹啉并吡咯烷-2-酮类衍生物及其应用

Publications (2)

Publication Number Publication Date
CN112771045A true CN112771045A (zh) 2021-05-07
CN112771045B CN112771045B (zh) 2022-04-19

Family

ID=69949734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980064561.9A Active CN112771045B (zh) 2018-09-30 2019-09-27 喹啉并吡咯烷-2-酮类衍生物及其应用

Country Status (11)

Country Link
US (1) US11230549B2 (zh)
EP (1) EP3845532B1 (zh)
JP (1) JP6997358B2 (zh)
KR (1) KR102345208B1 (zh)
CN (1) CN112771045B (zh)
AU (1) AU2019348132B2 (zh)
BR (1) BR112021005989A2 (zh)
CA (1) CA3114646C (zh)
MX (1) MX2021003739A (zh)
RU (1) RU2771314C1 (zh)
WO (1) WO2020063855A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469720A (zh) * 2018-04-20 2021-03-09 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN117355528A (zh) * 2021-05-08 2024-01-05 成都嘉葆药银医药科技有限公司 吡咯并三嗪类化合物的盐型、其晶型及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114746421A (zh) * 2019-11-19 2022-07-12 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
WO2017194632A1 (en) * 2016-05-11 2017-11-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN107889488A (zh) * 2015-04-02 2018-04-06 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
CN108348515A (zh) * 2015-11-05 2018-07-31 阿斯利康(瑞典)有限公司 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN108349971A (zh) * 2015-11-03 2018-07-31 阿斯利康(瑞典)有限公司 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647256A1 (en) * 2006-04-18 2007-10-25 Abbott Laboratories Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CN107889488A (zh) * 2015-04-02 2018-04-06 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
CN108349971A (zh) * 2015-11-03 2018-07-31 阿斯利康(瑞典)有限公司 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN108348515A (zh) * 2015-11-05 2018-07-31 阿斯利康(瑞典)有限公司 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
WO2017194632A1 (en) * 2016-05-11 2017-11-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469720A (zh) * 2018-04-20 2021-03-09 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN112469720B (zh) * 2018-04-20 2024-03-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN117355528A (zh) * 2021-05-08 2024-01-05 成都嘉葆药银医药科技有限公司 吡咯并三嗪类化合物的盐型、其晶型及其制备方法

Also Published As

Publication number Publication date
EP3845532A4 (en) 2021-11-17
CN112771045B (zh) 2022-04-19
BR112021005989A2 (pt) 2021-06-29
CA3114646A1 (en) 2020-04-02
CA3114646C (en) 2022-03-08
RU2771314C1 (ru) 2022-04-29
AU2019348132B2 (en) 2022-03-31
EP3845532A1 (en) 2021-07-07
US11230549B2 (en) 2022-01-25
AU2019348132A1 (en) 2021-05-20
EP3845532B1 (en) 2022-12-21
JP6997358B2 (ja) 2022-01-17
US20210380599A1 (en) 2021-12-09
JP2021529214A (ja) 2021-10-28
KR102345208B1 (ko) 2021-12-30
MX2021003739A (es) 2022-04-07
KR20210060613A (ko) 2021-05-26
WO2020063855A1 (zh) 2020-04-02

Similar Documents

Publication Publication Date Title
CN112771045B (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用
CN105189456B (zh) Kras g12c的共价抑制剂
CN112533916B (zh) 一种作用于crbn蛋白的三并环类化合物
CN112689627B (zh) 三环取代哌啶二酮类化合物
CN112654619B (zh) 三环并呋喃取代哌啶二酮类化合物
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN114456147A (zh) 氧取代氨基碳酸酯噻吩类化合物
CN117062810A (zh) 一系列双环取代的芳香羧酸类化合物
CN106928080A (zh) 稠合环γ‑氨基酸衍生物及其制备方法和在医药上的应用
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
CN114761411A (zh) 作为erk抑制剂的螺环类化合物及其应用
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
JP2023522725A (ja) ３－アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
CN116234551A (zh) 一类1,7-萘啶类化合物及其应用
CN113825755A (zh) 作为irak4抑制剂的咪唑并吡啶类化合物
CN116761806A (zh) 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物
CN115667258A (zh) 氟代吡咯并吡啶类化合物及其应用
CN112574278A (zh) 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
CN113045569A (zh) 用作ret激酶抑制剂的化合物及其应用
CN113316575A (zh) 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
JP7340680B2 (ja) Ｉｒａｋ４及びｂｔｋマルチターゲット阻害剤としてのオキサゾール化合物
WO2022063094A1 (zh) 四氢异喹啉衍生物及其应用
WO2023207991A1 (zh) 稠合喹唑啉类化合物及其应用
WO2024022234A1 (zh) 吡唑并吡啶类化合物在制备治疗包括中枢神经系统疾病的btk相关疾病的药物中的用途
CN113286790A (zh) 喹唑啉衍生物在制备治疗鼻咽癌药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041289

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant